|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500113321 |
|
最近更新日期: Date of Last Refreshed on: |
2025-11-27 09:15:16 |
|
注册时间: Date of Registration: |
2025-11-27 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
X连锁视网膜劈裂症 |
|
Public title: |
X-linked retinoschisis |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
一项针对X连锁视网膜劈裂症大型家系的Coats样反应研究,发现新型RS1基因变异 |
|
Scientific title: |
A study on Coats-like response in a large pedigree with X-linked retinoschisis revealed a novel RS1 gene variant. |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李文博 |
研究负责人: |
李文博 |
|
Applicant: |
Li Wenbo |
Study leader: |
Liwenbo |
|
申请注册联系人电话: Applicant telephone: |
+86 13512965239 |
研究负责人电话: Study leader's telephone: |
+86 18322792340 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
wenboli80@163.com |
研究负责人电子邮件: Study leader's E-mail: |
liwenbo1980s@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国天津市南开区复康路251号 |
研究负责人通讯地址: |
中国天津市南开区复康路251号 |
|
Applicant address: |
251, Fukang Road, Nankai District, Tianjin, China |
Study leader's address: |
251, Fukang Road, Nankai District, Tianjin, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
天津医科大学眼科医院 |
||
|
Applicant's institution: |
Tianjin Medical University Eye Hospital |
||
|
研究负责人所在单位: |
天津医科大学眼科医院 |
||
|
Affiliation of the Leader: |
Tianjin Medical University Eye Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025KY-67 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
天津医科大学眼科医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Tianjin Medical University Eye Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-10-10 00:00:00 |
||
|
伦理委员会联系人: |
陈卓 |
||
|
Contact Name of the ethic committee: |
Chen Zhuo |
||
|
伦理委员会联系地址: |
中国天津市南开区复康路251号 |
||
|
Contact Address of the ethic committee: |
251, Fukang Road, Nankai District, Tianjin, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 22 86428817 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
1006425222@qq.com |
|
研究实施负责(组长)单位: |
天津医科大学眼科医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Tianjin Medical University Eye Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国天津市南开区复康路251号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
251, Fukang Road, Nankai District, Tianjin, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-supporting project |
||||||||||||||||||||||
|
Target disease: |
X-linked juvenile retinoschisis |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
阐明合并 Coats 样反应的 X 连锁青少年视网膜劈裂症(XLRS)的临床特征与遗传基础,并确定 de novo RS1 突变(c.275G>A)与重症表型之间的关联。 |
||||||||||||||||||||||
|
Objectives of Study: |
To delineate the clinical features and genetic basis of X-linked juvenile retinoschisis (XLRS) with concomitant Coats-like response, and to establish the association between the de novo RS1 mutation (c.275G>A) and a severe phenotype. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
于天津医科大学眼科医院临床诊断为XLRS的病人及其亲属; |
||||||||||||||||||||||
|
Inclusion criteria |
Patients clinically diagnosed with XLRS at Tianjin Medical University Eye Hospital. |
||||||||||||||||||||||
|
排除标准: |
诊断为其他疾病的患者; |
||||||||||||||||||||||
|
Exclusion criteria: |
Patients diagnosed with other diseases; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-11-30 00:00:00至 To 2025-12-20 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-11-30 00:00:00 至 To 2025-12-20 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
国家生物信息中心网站(网址为:https://www.cncb.ac.cn/),预计共享时间为研究结束后6个月 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The National Bioinformation Center website (URL: https://www.cncb.ac.cn/) is expected to be shared 6 months after the completion of the study. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究所使用的数据均来自医疗电子病例以及病人术前检查报告 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
All data used in this study were extracted from electronic medical records and preoperative examination reports. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |